In today's Just The Facts...
Race Oncology has launched two new clinical programs for its lead drug RC220, targeting acute myeloid leukaemia and EGFR-mutated lung cancer. The move follows breakthroughs in understanding RC220’s mechanism, and aims to streamline regulatory pathways across major oncology markets.
Australian pharma group Bioxyne has secured about £850,000 in UK funding to build a new medicinal-cannabis manufacturing and distribution facility.
Lindian Resources has strengthened its leadership team by appointing Robert Rickie as commercial and supply manager. His arrival comes as construction advances at the Kangankunde Rare Earths Project in Malawi, bringing more than 15 years of mining-sector procurement and project delivery experience.
Anteris Technologies has reported strong 30-day clinical results for its DurAVR heart valve in 100 patients with small aortic annuli. The study showed low pressure gradients, large valve openings and no valve-related deaths.
#ASXNews #OncologyResearch #RaceOncology #LungCancerTreatment #CancerDrugDevelopment #Bioxyne #CannabisManufacturing #RareEarths #AnterisTechnologies